In a recent study, mean sensitivity was 85.5 percent and specificity 87 percent for detection of clear-cell renal cell carcinoma<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b>
\n<\/b><\/p>\n
MONDAY, Oct. 21, 2024 (HealthDay News) — \u2078\u2079Zr-labeled monoclonal antibody ([\u2078\u2079Zr]Zr-girentuximab) for positron emission tomography-computed tomography (PET-CT) is accurate for detecting patients with clear-cell renal cell carcinoma, according to a study published online in the October issue of The Lancet Oncology<\/em>.<\/p>\n Brian Shuch, M.D., from the University of California Los Angeles, and colleagues conducted a multicenter, phase 3 trial at 36 research hospitals and practices across nine countries to examine [\u2078\u2079Zr]Zr-girentuximab PET-CT imaging for detection and characterization of clear-cell renal cell carcinoma. Three hundred patients aged 18 years or older with an indeterminate renal mass 7 cm or smaller (cT1) suspicious for clear-cell renal cell carcinoma and scheduled for nephrectomy received a single dose of [\u2078\u2079Zr]Zr-girentuximab intravenously followed by abdominal PET-CT imaging. Surgery was performed up to 90 days after [\u2078\u2079Zr]Zr-girentuximab administration.<\/p>\n The primary analysis included 284 of the evaluable patients. The mean sensitivity and specificity of [\u2078\u2079Zr]Zr-girentuximab PET-CT imaging for detection of clear-cell renal cell carcinoma was 85.5 and 87.0 percent, respectively. There were no safety signals. Most of the adverse events were not or were unlikely to be related to [\u2078\u2079Zr]Zr-girentuximab; 74 percent of the 261 events occurred during or after surgery. Fifty-two serious adverse events were reported in 25 patients, of which 51 occurred after surgery. No treatment-related deaths occurred.<\/p>\n “Imaging using [\u2078\u2079Zr]Zr-girentuximab has the potential to change clinical practice in renal cell carcinoma, including staging and monitoring patients at high risk and detection of distant metastasis,” the authors write.<\/p>\n Several authors disclosed ties to biopharmaceutical companies, including Telix Pharmaceuticals, which funded the study.<\/p>\n